Saturday, February 21, 2026
ISSN 2765-8767
  • Survey
  • Podcast
  • Write for Us
  • My Account
  • Log In
Daily Remedy
  • Home
  • Articles
  • Podcasts
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    July 1, 2025

    The cost structure of hospitals nearly doubles

    July 1, 2025
    Navigating the Medical Licensing Maze

    The Fight Against Healthcare Fraud: Dr. Rafai’s Story

    April 8, 2025
  • Surveys

    Surveys

    How Confident Are You in RFK Jr.’s Health Leadership?

    How Confident Are You in RFK Jr.’s Health Leadership?

    February 16, 2026
    AI in Healthcare Decision-Making

    AI in Healthcare Decision-Making

    February 1, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
  • Home
  • Articles
  • Podcasts
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    July 1, 2025

    The cost structure of hospitals nearly doubles

    July 1, 2025
    Navigating the Medical Licensing Maze

    The Fight Against Healthcare Fraud: Dr. Rafai’s Story

    April 8, 2025
  • Surveys

    Surveys

    How Confident Are You in RFK Jr.’s Health Leadership?

    How Confident Are You in RFK Jr.’s Health Leadership?

    February 16, 2026
    AI in Healthcare Decision-Making

    AI in Healthcare Decision-Making

    February 1, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
Daily Remedy
No Result
View All Result
Home Politics & Law

Telehealth in Turmoil

America is waiting

Muhamad Aly Rifai, MD, FACP, FAPA, FACLP by Muhamad Aly Rifai, MD, FACP, FAPA, FACLP
January 31, 2025
in Politics & Law
0

The COVID-19 pandemic served as a catalyst for the rapid adoption of telehealth services across the United States. As in-person medical consultations became challenging, both healthcare providers and patients turned to virtual platforms to maintain continuity of care. Telehealth, encompassing a range of services from routine check-ups to specialized consultations, experienced unprecedented growth during this period. However, as the immediate crisis waned, the sustainability and integration of telehealth into the broader healthcare system faced numerous challenges, leading to a reevaluation of its role in American medicine.

 

In the early stages of the pandemic, telehealth emerged as a vital tool to bridge the gap between patients and healthcare providers. Regulatory bodies, recognizing the necessity, temporarily relaxed restrictions to facilitate virtual care. This included adjustments in reimbursement policies and the suspension of certain requirements, such as the in-person evaluation mandate for prescribing controlled substances. These measures enabled a swift transition to telehealth platforms, ensuring that patients continued to receive essential medical services without exposing themselves to potential viral transmission.

 

Telepsychiatry: A Case Study in Rapid Implementation

 

Telepsychiatry, the provision of psychiatric services through telecommunication technologies, exemplifies the rapid integration of telehealth during the pandemic. Historically, telepsychiatry was primarily utilized to serve rural and underserved populations with limited access to mental health professionals. The pandemic, however, necessitated its expansion to a broader patient base. I have been an early adopter of telepsychiatry, after finding myself at the forefront of this transformation. It is noted that the pandemic shifted telepsychiatry from a supplementary service to a mainstream necessity, highlighting its potential to address the burgeoning mental health crisis exacerbated by the pandemic.

 

Challenges Emerge Post-Pandemic

 

As the immediate threat of COVID-19 diminished, several challenges emerged that hindered the continued expansion of telehealth services:

 

Regulatory Uncertainty: The temporary waivers and relaxed regulations that facilitated the rapid adoption of telehealth during the pandemic began to expire. For instance, the Ryan Haight Act, enacted in 2008, requires an in-person evaluation before prescribing controlled substances via telemedicine. During the pandemic, this requirement was suspended, allowing for greater flexibility. However, as the public health emergency declarations ended, the reinstatement of such regulations created uncertainty among providers regarding the legality of continuing certain telehealth practices.

 

Reimbursement Discrepancies: Inconsistent reimbursement policies across different payers and states posed significant barriers. While Medicare expanded coverage for telehealth services during the pandemic, the future of such reimbursements remained uncertain. A report highlighted that without congressional action, most telehealth visits would not be covered by Medicare in 2025, potentially limiting access for many patients.

 

Technological Barriers: Despite advancements, technological challenges persisted. Issues such as poor internet connectivity, inadequate technical support, and user-unfriendly platforms hindered the effectiveness of telehealth services. A study found that 80% of providers indicated inadequate technical support, and many frequently encountered technical challenges, including inefficient system design and poor audio/visual quality.

 

 

Licensure and Interstate Practice: The lack of uniform licensure policies across states complicated the provision of telehealth services, especially for providers aiming to offer care to patients in multiple states. This fragmentation created administrative burdens and limited the scalability of telehealth solutions.

 

The Path Forward: Integrating Telehealth into Standard Care

 

To ensure that telehealth remains a viable component of the American healthcare system, several steps must be taken:

 

Regulatory Reforms: Policymakers need to establish clear and consistent regulations that support the integration of telehealth into routine care. This includes revisiting laws like the Ryan Haight Act to balance the need for controlled substance regulation with the benefits of telemedicine.

 

Standardized Reimbursement Policies: Creating uniform reimbursement frameworks across payers and states will incentivize providers to continue offering telehealth services. Ensuring that telehealth visits are reimbursed at parity with in-person visits can promote broader adoption.

 

Investment in Technology Infrastructure: Addressing technological barriers is crucial. Investments in broadband infrastructure, especially in rural areas, and the development of user-friendly telehealth platforms can enhance the patient and provider experience.

 

Interstate Licensure Compacts: Encouraging states to participate in licensure compacts can facilitate interstate telehealth practice, allowing providers to reach underserved populations more effectively.

 

Public Awareness and Education: Educating both providers and patients about the benefits and limitations of telehealth can promote its appropriate use. Training programs for providers can enhance their comfort with telehealth technologies, while patient education can alleviate apprehensions related to virtual care.

 

The pandemic underscored the potential of telehealth to enhance healthcare delivery in the United States. However, realizing this potential requires addressing the regulatory, financial, technological, and educational challenges that have emerged. By proactively tackling these issues, stakeholders can ensure that telehealth becomes a permanent and effective component of the healthcare landscape, rather than a temporary solution to a crisis.

ShareTweet
Muhamad Aly Rifai, MD, FACP, FAPA, FACLP

Muhamad Aly Rifai, MD, FACP, FAPA, FACLP

Muhamad Aly Rifai is a Syrian American internist and psychiatrist who was accused by the government with fraud but exonerated in a jury trial.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Videos

This conversation focuses on debunking myths surrounding GLP-1 medications, particularly the misinformation about their association with pancreatic cancer. The speaker emphasizes the importance of understanding clinical study designs, especially the distinction between observational studies and randomized controlled trials. The discussion highlights the need for patients to critically evaluate the sources of information regarding medication side effects and to empower themselves in their healthcare decisions.

Takeaways
GLP-1 medications are not linked to pancreatic cancer.
Peer-reviewed studies debunk misinformation about GLP-1s.
Anecdotal evidence is not reliable for general conclusions.
Observational studies have limitations in generalizability.
Understanding study design is crucial for evaluating claims.
Symptoms should be discussed in the context of clinical conditions.
Not all side effects reported are relevant to every patient.
Observational studies can provide valuable insights but are context-specific.
Patients should critically assess the relevance of studies to their own experiences.
Engagement in discussions about specific studies can enhance understanding

Chapters
00:00
Debunking GLP-1 Medication Myths
02:56
Understanding Clinical Study Designs
05:54
The Role of Observational Studies in Healthcare
Debunking Myths About GLP-1 Medications
YouTube Video DM9Do_V6_sU
Subscribe

2027 Medicare Advantage & Part D Advance Notice

Clinical Reads

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

by Daily Remedy
February 15, 2026
0

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!

Twitter Updates

Tweets by TheDailyRemedy

Popular

  • The Prevention Gap in Dementia Care

    The Prevention Gap in Dementia Care

    0 shares
    Share 0 Tweet 0
  • Healthcare in Space

    1 shares
    Share 0 Tweet 0
  • Healthcare Natural Rights

    0 shares
    Share 0 Tweet 0
  • Heat Safety Tips Every Pregnant Mother Should Know

    0 shares
    Share 0 Tweet 0
  • How Patients Can Retake the Emergency Care Experience

    1 shares
    Share 0 Tweet 0
  • 628 Followers

Daily Remedy

Daily Remedy offers the best in healthcare information and healthcare editorial content. We take pride in consistently delivering only the highest quality of insight and analysis to ensure our audience is well-informed about current healthcare topics - beyond the traditional headlines.

Daily Remedy website services, content, and products are for informational purposes only. We do not provide medical advice, diagnosis, or treatment. All rights reserved.

Important Links

  • Support Us
  • About Us
  • Contact us
  • Privacy Policy
  • Terms and Conditions

Join Our Newsletter!

  • Survey
  • Podcast
  • About Us
  • Contact us

© 2026 Daily Remedy

No Result
View All Result
  • Home
  • Articles
  • Podcasts
  • Surveys
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner

© 2026 Daily Remedy